McKesson 2011 Annual Report Download - page 5
Download and view the complete annual report
Please find page 5 of the 2011 McKesson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2 -
3 -
4 -
5 -
6 -
7 -
8 -
9 -
10 -
11 -
12 -
13 -
14 -
15 -
16 -
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
 |
 |
$2.1 billion of common stock, paid $171 million in
dividends (reflecting a 50% dividend increase), made
$388 million in internal investments and completed
the $2.1 billion purchase of US Oncology. We plan
to maintain our portfolio approach in fiscal 2012. In
April 2011, our board authorized the repurchase of
an additional $1 billion of common stock, bringing
the total authorization to approximately $1.5 billion,
and approved a new policy increasing our quarterly
dividend from $0.18 to $0.20 per share. These
actions demonstrate our confidence in our business
and the stability of our future cash flow.
Summary and Outlook
Looking ahead, we expect the forces that have
produced attractive market conditions for McKesson
will continue in fiscal 2012. Access, quality and cost
will remain critical healthcare challenges over the
next five years, compelling providers, manufacturers
and payers to seek broad solutions that enable
them to improve financial, clinical and operational
performance. Against this backdrop, we see the
following positive trends in the core areas that drive
McKesson’s financial success:
•Growingmarketforpharmaceuticalsandmedical
supplies, with particular opportunities to expand
our generics business and address the nearly
$300 billion untapped market opportunity created
by poor medication adherence.
•Expandinguseofhealthcareinformation
technology, driven by ARRA, the need to integrate
business and clinical processes, and the pressure
on all stakeholders to improve efficiency.
•Acceleratingdemandforconnectivitysolutions,
spurred by the need to coordinate care across
settings, optimize financial performance and
improve quality.
“We are uniquely positioned to help
improve the business and clinical
performance of all sectors of the
healthcare system, leading to better
results for our customers, better
health for patients and better returns
to our stockholders.”
Industry Leadership
In March 2011, McKesson was rated among the world’s most admired companies in healthcare by FORTUNE Magazine
for the second year in a row. Currently ranked 15th on the Fortune 500, McKesson is:
•#1inpharmaceuticaldistributionintheU.S.andCanada
•#1inpharmaceuticaldistributionforgenericpharmaceuticals
•#1inmedical-surgicaldistributiontoalternatecaresites
•#1inmedicalmanagementandclaimsauditing
•#2inspecialtydistributionandservices
Making the business of healthcare run better by
improving the health and vitality of our customers
and supplier partners remains our core focus. We
know that every improvement in the operation,
infrastructure and delivery of care increases safety,
reduces costs and improves outcomes. Our leadership
in these areas delivers value to our stockholders, and
most importantly, leads to better health for all.
On behalf of the Board of Directors and our 36,400
dedicated employees, thank you for your commitment
to McKesson.
John H. Hammergren
Chairman, President and Chief Executive Officer
McKesson Corporation